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Protocol
AbstrACt
Introduction The clinical syndrome of neonatal sepsis, 
comprising signs of infection, septic shock and organ 
dysfunction in infants ≤4 weeks of age, is a frequent 
sequel to bloodstream infection and mandates urgent 
antimicrobial therapy. Bacterial characterisation and 
antimicrobial susceptibility testing is vital for ensuring 
appropriate therapy, as high rates of antimicrobial 
resistance (AMR), especially in low-income and middle-
income countries, may adversely affect outcome. Ho Chi 
Minh City (HCMC) in Vietnam is a rapidly expanding city 
in Southeast Asia with a current population of almost 
8 million. There are limited contemporary data on the 
causes of neonatal sepsis in Vietnam, and we hypothesise 
that the emergence of multidrug resistant bacteria is an 
increasing problem for the appropriate management of 
sepsis cases. In this study, we aim to investigate the major 
causes of neonatal sepsis and assess disease outcomes 
by clinical features, antimicrobial susceptibility profiles and 
genome composition.
Method and analysis We will conduct a prospective 
observational study to characterise the clinical and 
microbiological features of neonatal sepsis in a major 
children’s hospital in HCMC. All bacteria isolated from 
blood subjected to whole genome sequencing. We will 
compare clinical variables and outcomes between different 
bacterial species, genome composition and AMR gene 
content. AMR gene content will be assessed and stratified 
by species, years and contributing hospital departments. 
Genome sequences will be analysed to investigate 
phylogenetic relationships.
Ethics and dissemination The study will be conducted 
in accordance with the principles of the Declaration of 
Helsinki and the International Council on Harmonization 
Guidelines for Good Clinical Practice. Ethics approval has 
been provided by the Oxford Tropical Research Ethics 
Committee 35-16 and Vietnam Children’s Hospital 1 
Ethics Committee 73/GCN/BVND1. The findings will be 
disseminated at international conferences and peer-
reviewed journals.
trial registration number ISRCTN69124914; Pre-results.
bACkground 
Neonatal sepsis is widely recognised as a clin-
ical syndrome of systemic inflammation in 
response to, or occurring the same time as, 
a possible or proven infection (frequently 
by identifying bacterial bloodstream infec-
tion) occurring in children ≤28 days of age. 
A consensus definition of neonatal sepsis has 
remained a challenge.1 Globally, the incidence 
strengths and limitations of this study
 ► Little is known about the current aetiological agents 
of neonatal sepsis in Vietnam. This prospective 
study will integrate clinical assessments with 
microbiological and detailed whole genome 
sequence data to characterise the aetiology and 
outcome of neonatal sepsis in this high-mortality 
setting.
 ► This study is being performed at the largest 
secondary/tertiary paediatrics centre in Southern 
Vietnam. Data collection at a single site may limit 
the applicability to other hospitals in the country.
 ► Other limitations encountered in designing this 
study include ethical issues involved in collecting 
samples from severely ill neonates, lack of 
current transferable definitions for neonatal sepsis 
phenotypes and stochastic variations in numbers 
of cases recruited due to seasonal variation and 
continuous changes in community antimicrobial and 
vaccine use.
 ► Some contamination of blood cultures is unavoidable 
in our setting and therefore accurately classifying 
some isolates as true pathogens in certain cases 
may be challenging.
2 Toan ND, et al. BMJ Open 2018;8:e019611. doi:10.1136/bmjopen-2017-019611
Open Access 
of neonatal sepsis is estimated to be 1–5 cases/1000 live 
births but is lower in full-term neonates (1–2 cases/1000 
live births), in whom the incidence is higher in men than 
women.2 3 Early-onset sepsis is defined as the start of sepsis 
symptoms within 72 hours of birth1 4 and is often caused 
by vertical transmission of pathogens during delivery as a 
result of chorioamnionitis or maternal genital tract colo-
nisation.5 Late-onset sepsis, occurring after 72 hours from 
birth,1 6 may be caused by similar vertical transmission or 
horizontal transmission mechanisms due to direct contact 
with the surrounding environment, attendant healthcare 
staff or any invasive procedures.7 
neonatal sepsis in southeast Asia
Neonatal sepsis remains a leading cause of neonatal hospital 
admission, morbidity and mortality in low-income and 
middle-income countries (LMICs).8 In this setting, bacterial 
infection, including bacteraemia, is complicated by multi-
drug resistance, particularly related to healthcare acquired 
infection, and effective management of neonatal sepsis is 
increasingly problematic.8 Recently, WHO has acknowl-
edged the problem of antimicrobial resistance (AMR) as 
an endemic and widespread problem in LMICs.9 In many 
LMICs untreatable bacterial infections with broadly AMR 
pathogens are no longer a threat but a common reality. 
AMR in LMICs represents one of the biggest threats to 
global health and are one of the greatest current challenges 
in infectious disease research.
While AMR is an issue with all types of bacterial infec-
tion, the issue is most acute in management of clinical 
sepsis. This is a particular problem in neonates due to high 
mortality/morbidity rates and the timely need for rapid 
detection and treatment of the causative pathogen. Sepsis 
demonstrates extensive geographical diversity in both aeti-
ology and proportions of AMR bacteria isolated.10 11 Under-
standing the local and regional epidemiology of sepsis 
in hospitalised neonates is crucial in the development of 
rational management and treatment guidelines, especially 
in high-risk AMR LMICs locations like Vietnam.
sepsis and AMr in Vietnam
Bacterial sepsis is classified into two major groups 
according to place of acquisition. Hospital-acquired sepsis 
is defined in patients with clinical manifestations of sepsis 
and a confirmatory blood culture collected >48 hours 
following hospital admission.12 Hospital-acquired sepsis 
is a major threat to patient safety, and in locations with 
poor surveillance and infection control programme such 
infections are associated with high mortality rates. The 
incidence of AMR bloodstream infections in Vietnam has 
increased over recent years and is predicted to increase 
further.13 This trend has comprised an increase in both 
Gram-negative and Gram-positive pathogens, chiefly Esch-
erichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, 
Staphylococcus aureus and enterococci.
Community-acquired sepsis is also an important cause 
of fever among patients admitted to hospitals across South 
and Southeast Asia. In our practice, community-acquired 
sepsis is defined as the presence of sepsis with a confir-
matory blood culture collected within 48 hours after 
hospital admission.14 Distinguishing bacterial infections 
from other common causes of fever, such as malaria or 
dengue, can be challenging without diagnostic labora-
tory support.15 Important causes of community-acquired 
bloodstream infection (CA-BSI) in LMICs include Salmo-
nella serovars Typhi and Paratyphi A, E. coli, K. pneumoniae, 
S. aureus and Streptococcus pneumoniae. We have reported 
increasing levels of AMR in these common communi-
ty-acquired pathogens and highlighted the difficulties of 
accurate diagnosis with traditionally available diagnostics. 
For example in Nepal and Vietnam antimicrobial resis-
tance in Salmonella Typhi and Salmonella Paratyphi A has 
severely restricted the options available for antimicrobial 
treatment.16
Changing aetiology of bsI in Vietnam
The aetiology of CA-BSI in Vietnam has changed consid-
erably over the 20 years. A previous study documented the 
decline of Salmonella Typhi from 2002, the predominant 
pathogen until this point and the subsequent increase 
in non-typhoidal Salmonella and other opportunistic 
HIV-associated pathogens.17 This shift is likely to reflect a 
changing landscape of infectious disease related to the HIV 
epidemic, urbanisation and secondary social determinants 
within Vietnam. Vietnam, as with many countries in Asia, is 
undergoing a rapid economic transition, and programmes 
to improve sanitary conditions have reduced the overall 
risk of waterborne infections. HIV-associated opportu-
nistic pathogens have now emerged as the leading cause of 
bloodstream infections and the primary cause of mortality 
in hospitalised adult patients in this location. These studies 
were performed at the Hospital for Tropical diseases in Ho 
Chi Minh City and thus included mainly adults, including 
those with HIV, and children but not neonates.18–20 There-
fore, these observations may not be fully representative of 
the situation in neonates.
knowledge gaps
Little is known about contemporary antimicrobial suscep-
tibility patterns and their underlying genetic determi-
nants in the major causes of neonatal bacterial of sepsis 
in Vietnam. Furthermore, the impact of antimicrobial 
susceptibility and other virulence factors on disease 
progression and outcome in neonates in LMICs is also 
not well documented. To address these issues, we aim 
to investigate the aetiology of pathogens associated with 
bacterial sepsis in neonates and to detail the effects of 
reduced antimicrobial susceptibility on the outcome 
of sepsis in neonates. This will be a clinical and micro-
biology laboratory research project between Children’s 
Hospital 1 and the Oxford University Clinical Research 
Unit (OUCRU) in Vietnam. This study will be a conduit 
for introducing molecular biology for bacteriology into 
routine hospital care at this children’s hospital and will 
lead to future studies investigating appropriate empirical 
treatment for bacteraemia and the impact of antimicrobial 
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resistance on the outcome of sepsis in the paediatric and 
neonatal population in Vietnam.
rationale, aim and objectives
To understand the causes of neonatal sepsis and to best 
inform antimicrobial treatment regimes in our setting, 
we will perform a prospective observational study at Chil-
dren’s Hospital 1 in Vietnam from 2017 to 2019. There 
are limited contemporary data on the causes of bacte-
rial sepsis in neonates in Vietnam. We hypothesise that 
there have been recent increases in multidrug resistant 
Gram-negative bacteria causing sepsis in this high-risk 
group and that methicillin-resistant S. aureus has emerged 
as an important pathogen. We further aim to investigate 
the clinical features, major causes of neonatal sepsis and 
the distribution of pathogens by departments, their antimi-
crobial susceptibility patterns and the genomic profiles of 
the isolated bacteria as well as their association with disease 
outcomes.
Primary objectives
 ► To describe the clinical characteristics of neonates 
with sepsis, including community and hospital-ac-
quired sepsis, early-onset and late-onset sepsis.
 ► To determine the aetiology of neonatal sepsis and 
the distribution of pathogens by clinical departments 
including the Neonatology Department and the 
Neonatal Intensive Care Unit.
 ► To determine the antimicrobial susceptibility profiles 
of the bacteria causing neonatal sepsis and the AMR 
profiles occurring in community and hospital-ac-
quired infections.
 ► To analyse the impact of specific bacteria and AMR 
profile on the outcomes (mortality, length of stay and 
cost of treatment) of neonates with sepsis.
 ► To determine the genome sequences of bacterial 
strains associated with neonatal sepsis.
secondary objectives
 ► To determine the AMR profiles and gene distribution 
of isolated bacteria by clinical departments to add 
insight into the circulation of bacteria associated with 
hospital acquired infections.
 ► To study the genes catalysing resistance to antimi-
crobials commonly used to treat neonatal sepsis 
(specifically third/fourth generation cephalosporins, 
fluoroquinolones and carbapenems).
MEthods
study design
This protocol describes a prospective, non-interventional, 
observational study to characterise the clinical features of 
neonates with sepsis at Children’s Hospital 1 in Ho Chi 
Minh City in Vietnam between 2017 and 2019, the micro-
bial population structure, antimicrobial susceptibility 
patterns and the AMR genes of the bacteria causing that 
sepsis. All organisms isolated from blood will be stored 
and archived for molecular characterisation.
study site
Children’s Hospital 1 (Neonatology Department, 
Neonatal Intensive Care Unit, Microbiology Department) 
is in Ho Chi Minh City in Vietnam. The estimated popu-
lation of the city was 8.4 million in 2016, and 23.8% are 
children 0–14 years of age.21 Children’s Hospital 1 is the 
largest tertiary paediatrics centre in Southern Vietnam 
with 1400 inpatient beds and >1600 staff members. The 
hospital receives ~1.5 million outpatient visits and 95 000 
admissions each year. Care is provided to all children <15 
years old from Ho Chi Minh City and other provinces of 
Southern Vietnam. The neonatal centre at this hospital 
currently has 120 inpatient beds for the neonatology 
department and additional 30 beds in the neonatal inten-
sive care unit. The overall mean rate of positive blood 
cultures in our hospital is 7% per year.
dEfInItIons
definition of sepsis
A sepsis episode in this study is defined as isolation of a 
clinically relevant pathogen from ≥1 blood culture, drawn 
from a neonate with ≥1 clinical or laboratory sign of sepsis 
(table 1).22
diagnosis of neonatal sepsis
Systematic guidelines concerning which patients should 
have blood cultures performed are not strictly defined in 
our hospital, although blood culture results are used to 
confirm the diagnosis of sepsis in neonates with a compat-
ible clinical presentation. We use the criteria suggested by 
the European Medicines Agency in 2010 for the diagnosis 
of ‘probable sepsis’ and ‘confirmed sepsis’ in neonates22:
 ► Probable sepsis: ≥2 clinical and ≥2 laboratory signs;
 ► Confirmed sepsis: ≥1 positive culture of a pathogen 
and ≥1 clinical or laboratory sign.
sAMPlE sIzE
In this prospective observational study, we aim to recruit 
all patients with available data who fulfil the inclusion 
criteria and are admitted to Children’s Hospital 1 in 
Ho Chi Minh City in Vietnam from 2017 to 2019. Based 
on retrospective surveillance data, we estimate recruit-
ment of 800 participants during the study period. Blood 
cultures will be performed in all cases, we expect to 
yield ~400 bacterial isolates.
Participant selection and recruitment
Inclusion criteria
Neonates (≤1 month of age) with a diagnosis of ‘probable’ 
or ‘confirmed’ sepsis who have had a blood culture taken 
and who are an inpatient at Children’s Hospital 1 will be 
recruited into the study after written informed consent 
has been given by a parent or guardian.
Exclusion criteria
Patients will be excluded when informed consent is not 
provided, the length of hospital stay less than 24 hours, 
imminent and inevitable death or the patient has been 
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previously recruited in the study. Investigators will review 
all of the mortality records during the time period of the 
study to try and identify how many of these cases may have 
been missed and whether there were any common char-
acteristics in these participants.
Identification of participants
All doctors and nurses in the Department of Neonatology 
and Neonatal Intensive Care Unit of the study hospital 
will be informed about, and trained for, this clinical inves-
tigation. In addition, those working in the Department 
of Neonatology and Neonatal Intensive Care Unit will 
also be involved in the study. These staff will be trained to 
identify eligible patients and how to notify investigators.
Informed consent
Trained, Good Clinical Practice   (GCP) accredited, 
members of the study team will collect informed consent. 
The team will discuss the study with the accompanying 
parent/guardian, or, if both parents are deceased or not 
actively involved in child care, the main long-term carer of 
the child will be accepted as the guardian and considered 
able to give consent for the study. Study staff will describe 
the purpose of the study, the study procedures, possible 
risks/benefits, the rights and responsibilities of partici-
pants and alternatives to enrolment. The parent/guardian 
will be invited to ask questions, which will be addressed 
by study staff, and they will be provided with appropriate 
contact numbers if they have any subsequent questions. If 
the parent/guardian agrees for the child to participate, they 
will be asked to sign and date an informed consent form. 
A copy of the patient information sheet and the informed 
consent form will be given to them to keep. In addition to 
the procedures above, illiterate signatories will have the 
informed consent form read to them in the presence of a 
witness who will sign to confirm this. The parent/guardian 
can withdraw from the study at any time (verbally) without 
affecting the care that the child will receive. If the parent/
guardian decides at any time to take the child out of the 
study, no new information will be collected. However, infor-
mation collected on the child up until that point will still be 
used. All patient information sheets and consent forms will 
be written in the local language and will use terms that are 
easily understandable.
study procedures
An investigator will routinely record and collect demo-
graphic, clinical and laboratory information of the 
patients, the date of blood draw, the number of blood 
culture bottles inoculated, the result of the culture 
(whether positive or negative) and the susceptibility of the 
isolate to commonly used antimicrobials. Data from these 
records will be subsequently entered into CliRes Data 
Management System of OUCRU. These will be source 
data for this study. The number of patients admitted 
to the hospital annually will be obtained from hospital 
records. As part of this study, we request that all isolates 
from blood are stored and archived at –80°C. These 
isolates will be recultured and the identification will be 
reconfirmed. Selected isolated organisms from blood will 
have further molecular characterisation at a later date.
dAtA CollECtIon
demographic and clinical assessments
Data on neonatal sepsis at Children’s Hospital 1 will be 
collected to the case report form. These data will include 
administrative data, demographic data, clinical characteris-
tics, laboratory results, diagnoses, treatments and outcomes. 
Table 1 Clinical and laboratory signs of neonatal sepsis
Clinical signs of sepsis  ► Abnormal body temperature (core temperature >38.5°C or <36°C and/or temperature instability);
 ► Cardiovascular instability (bradycardia (mean heart rate <10th percentile for age in the absence 
of external vagal stimulus, beta blockers or congenital heart disease or otherwise unexplained 
persistent depression over a 0.5–4 hour time period) or tachycardia (mean heart rate >2 SD 
above normal for age in the absence of external stimulus, chronic unexplained persistent 
elevation over a 0.5–4 hour time period) and/or rhythm instability, reduced urinary output (<1 mL/
kg/hour), hypotension (mean arterial pressure <5th percentile for age), mottled skin, impaired 
peripheral perfusion);
 ► Respiratory instability (apnoea episodes or tachypnoea episodes (mean respiratory rate >2 SD 
above normal for age) or increased oxygen requirements or requirement for ventilator support);
 ► Gastrointestinal (feeding intolerance, poor sucking, abdominal distension);
 ► Skin and subcutaneous lesions (petechial rash, sclerema);
 ► Non-specific (irritability, lethargy, hypotonia).
Laboratory signs of sepsis  ►White cells <4×109 cells/L or >20×109 cells/L
 ► Immature to total neutrophil ratio (I/T) >0.2
 ► Platelet count <100×109/L
 ► C reactive protein>15 mg/L or procalcitonin ≥2 ng/mL
 ► Glucose intolerance (hyperglycaemia (blood glucose >180 mg/dL or 10 mmol/L) or 
hypoglycaemia (blood glucose <45 mg/dL or 2.5 mmol/L))
 ►Metabolic acidosis (base excess <–10 mEq/L or serum lactate >2 mmol/L)
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The Neonatal Therapeutic Intervention Scoring System 
will be used to estimate the disease severity.23
Microbiological assessments
Available routine microbiology data on neonatal blood-
stream infections Children’s Hospital 1. These data will 
include pathogenic agents isolated from blood culture 
and antimicrobial susceptibility profile of isolated 
bacteria (routine panel of antimicrobials). Selected 
isolates will have additional antimicrobial susceptibility 
testing, molecular analysis for antimicrobial resistance 
genes and genome sequencing of selected strains defined 
by antimicrobial susceptibility data.
lAborAtory MEthods
Microbiology testing
When required for checking or to non-routine anti-
microbials, antimicrobial susceptibility testing of the 
pathogens isolated will be performed by disk diffu-
sion using guidelines established by the Clinical and 
Laboratory Standards Institute and, when required, 
by minimum inhibitory concentration estimation 
using the VITEK 2 COMPACT automated machine. 
Antimicrobial susceptibilities tested will include nali-
dixic acid, ciprofloxacin, ceftriaxone, cefepime, ampi-
cillin, trimethoprim–sulfamethoxazole, azithromycin, 
imipenem, colistin and amikacin for all Gram-neg-
ative organisms and oxacillin and vancomycin in 
Gram-positive organisms. The production of extend-
ed-spectrum beta lactamases (ESBL) will be investi-
gated using the double-disc synergy test by comparing 
zone sizes between ceftazidime discs against ceftazi-
dime–clavulanic acid discs and cefotaxime discs 
against cefotaxime–clavulanic acid discs. Isolates with 
an increase in diameter of inhibitory zone of equal to 
or more than 5 mm by the synergy of clavulanate will 
be considered ESBL positive.
Organisms including coryneforms (Corynebacte-
rium, etc), Micrococci, Propionibacterium, Bacillus, alpha 
haemolytic Streptococci, environmental Gram-negative 
bacilli and non-pathogenic Neisseria will be considered 
potential contaminants. The pathogen-contaminant 
decision will be made based on the clinical relevance 
of the isolated bacteria and the independent assess-
ments by two qualified medical microbiologists. If there 
is disagreement, then the case will be discussed until a 
decision is reached.
bacterial storage
Organisms will be subcultured onto 5% blood agar and 
the purity of the isolate will be tested before storage in 
20% glycerol at –80°C.
Isolation of nucleic acids
Isolates will be recultured and their identification 
rechecked. DNA will be extracted from bacterial isolates 
using the Wizard Genomic DNA Extraction Kit (Promega, 
Fitchburg, Wisconsin, USA). The quality and concentra-
tion of the DNA will be assessed using a nanodrop spectro-
photometer prior to PCR amplification and the Quant-IT 
Kit (Invitrogen, Carlsbad, California, USA) prior to DNA 
sequencing.
PCr for resistance genes
The primary focus study is to investigate the distribution 
of antimicrobial resistance genes in bacteria causing 
neonatal sepsis. Therefore, all Gram-negative organisms 
will be investigated by PCR to detect genes catalysing 
resistance to cephalosporins, fluoroquinolones and 
carbapenems. Conventional PCR will be performed for 
the following classes of resistance genes using previously 
described methods. The multiplex and monoplex PCRs 
are described in these publications. PCR will be used to 
detect AmpC, ESBL (including CTX-M15), NDM, qnr, 
OXA, KPC and mecA/Van.11 24–29
genome sequencing
Selected organisms (on the basis of their susceptibility 
profiles and resistance gene content) will be genome 
sequenced. We aim to sequence the greatest cross-section 
of organism groups as possible (ie, all Staphylococci or all 
Klebsiella). Selected bacterial isolates will be sequenced 
at OUCRU in Vietnam. Briefly, index-tagged paired end 
Illumina sequencing libraries will be prepared using one 
of 96 unique indexing tags as previously described. These 
will be combined into pools of uniquely tagged libraries 
and sequenced on the Illumina Genome Analyzer or 
HiSeq sequencer according to manufacturer’s protocols 
to generate tagged 54–100 bp paired-end reads. This is 
previously approached for describing Gram-negative 
organisms and Staphylococcus.20 30 31
AnAlysIs PlAn
statistical comparisons
Data will be presented in the form of tables and bar charts 
for descriptive variables, that is, number of organisms 
per year and number of AMR organisms per year. Statis-
tical comparisons of features between groups (positive/
negative blood culture, Gram-negative/Gram-positive 
bacteria, survival/non-survival, etc) and time trend anal-
ysis of the cultured isolates by month and the antimicro-
bial susceptibility patterns will be conducted. These data 
will be placed in the context of the broader population 
by comparison of these data with historical laboratory 
records of pathogens isolated from patients with blood-
stream infections. Historical data from both neonates and 
older children will be analysed descriptively, and where 
appropriate, time trend analyses will be performed to 
determine significant alterations in bloodstream infec-
tion aetiology. All statistical analysis will be performed 
using Stata V.14 and R. P values of ≤0.05 will be consid-
ered significant.
Antimicrobial resistance genes and genome sequencing
The presence/absence of antimicrobial resistance genes 
will be reported as proportions per organism and then 
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stratified by organism, year and hospital department. 
Genome sequences will be determined to study phylo-
genetic relationships, the presence/absence of virulence 
genes and also AMR gene content and first analysed 
by species and then group by their Gram-stain results. 
Briefly, for phylogenetic analysis, chromosomal single 
nucleotide polymorphism (SNP) alleles will be concate-
nated for each strain to generate a multiple alignment 
of all SNPs. For maximum likelihood (ML) analysis, 
RAxML will be run using the generalised time-reversible 
model and 1000 bootstrap pseudoreplicate analyses were 
performed to assess support for the ML phylogeny. Root-
to-tip branches will be extracted from the ML tree using 
the programme TreeStat. The relationship between root-
to-tip distances and year of isolation will be analysed using 
linear regression. For Bayesian Evolutionary Analysis 
Sampling Trees (BEAST) analysis (V1.6), a GTR+Γ substi-
tution model and defined tip dates as the date of isola-
tion will be used.30 31 To detect the presence or absence of 
genes read sets will be assembled using the de novo short 
read assembler Velvet and Velvet Optimizer. Organism 
specific read sets will then be aligned to the pangenome. 
Taxonomic investigation of accessory and AMR genes will 
be performed using MG-RAST V.3.2.
Ethics, regulatory approvals and governance
This study is sponsored by the University of Oxford 
and will be monitored by the Clinical Trials Unit at 
OUCRU. The Principal investigator (SB) will ensure 
that this study is conducted in accordance with the 
principles of the Declaration of Helsinki and the 
terms of approval of the appropriate ethical commit-
tees.32 The study will be conducted in full conformity 
with relevant regulations and with the International 
Council on Harmonisation Guidelines for GCP.33 
This protocol and the relevant supporting document 
have already had the approvals of the Oxford Trop-
ical Research Ethics Committee and the institutional 
review board of Children’s Hospital 1. The investiga-
tors will submit and, where necessary, obtain approval 
from the above parties for all substantial amendments 
to the original approved documents.
dissemination and public engagement
Data from this study will be of interest to the scientific 
and clinical research communities. An informative 
resource for managing sepsis will be made available to 
local clinicians, clinical microbiologists and infection 
control policy developers. Study data will be reported 
according to the Strengthening the Reporting of 
Observational studies in Epidemiology guidance for 
reporting observational studies.34 The authors (and 
their respective positions in the author list) will be 
agreed prior to the start of the study in accordance 
with the guidelines of the International Committee of 
Medical Journal Editors. In line with Wellcome Trust 
policy that the results of publicly funded research 
should be freely available, manuscripts arising from 
this study will be submitted to peer-reviewed jour-
nals which enable Open Access. In line with research 
transparency and greater access to data sharing policy 
of OUCRU in Vietnam will be implemented. This 
policy is based on a controlled access approach with a 
restriction on data release that would compromise an 
ongoing trial or study. Data exchange complies with 
Information Governance and Data Security Policies in 
all of the relevant countries.
dIsCussIon
As a conduit for introducing molecular biology for 
bacteriology into routine hospital care in Vietnam, the 
Table 2 Study summary
Title
The clinical features, antimicrobial susceptibility patterns and genomics of bacteria causing 
neonatal sepsis in a children’s hospital in Vietnam
Design Observational prospective study
All organisms isolated from blood will be stored and archived for molecular characterisation
Participants Neonates (≤1 month of age) with sepsis
Planned enrolment period 2017–2019
Primary objectives  ► To investigate the clinical characteristics of neonatal sepsis;
 ► To define the aetiology, the percentage of positive blood culture and major causes of sepsis;
 ► To investigate the antimicrobial susceptibilities of the pathogens causing sepsis and the rate of 
antimicrobial resistance;
 ► To measure the impact of sepsis on the severity of disease and the outcomes (mortality rate, 
length of stay and cost of treatment) of hospitalised neonates;
 ► To analyse the genome sequences of bacterial strains causing neonatal sepsis.
Secondary objectives  ► To analyse the antimicrobial resistance profiles and gene distribution by clinical departments to 
add insight into the circulation of bacteria causing nosocomial infections;
 ► To study the genes catalysing resistance to the antimicrobials commonly used to treat neonatal 
sepsis (specifically third-generation/fourth-generation cephalosporins, fluoroquinolones and 
carbapenems).
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study is unique and is planned to lead to future studies 
investigating appropriate empirical treatment for bacte-
raemia and the impact of AMR on the outcome of sepsis 
in the neonatal and paediatric population in Vietnam. 
By studying and defining disease aetiology, antimicrobial 
susceptibility patterns and disease outcome, we plan to 
develop an improved approach to managing bloodstream 
infections in our setting, and we will use these data to 
initiate intervention studies focused on preventing sepsis 
with AMR pathogens in neonates. Table 2 shows the 
summary of this study.
duration and current status of study
The first patient was recruited in January 2017. At the 
current time, the recruitment is ongoing. The expected 
end date for recruitment is 31 December 2019. We expect 
to have completed our data analysis plan with a view of 
results by June 2020.
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